Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

被引:46
作者
Drab, Scott R. [1 ,2 ]
机构
[1] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15261 USA
[2] Univ Diabet Care Associates, Jeannette, PA USA
来源
PHARMACOTHERAPY | 2010年 / 30卷 / 06期
关键词
type; 2; diabetes; incretin-based therapies; glucagon-like peptide-1; GLP-1; dipeptidyl peptidase-4; DPP-4; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; BETA-CELL FUNCTION; DEPENDENT INSULINOTROPIC POLYPEPTIDE; CARDIOVASCULAR RISK-FACTORS; METFORMIN-TREATED PATIENTS; DRUG-NAIVE PATIENTS; GLYCEMIC CONTROL; DOUBLE-BLIND; EXENATIDE EXENDIN-4;
D O I
10.1592/phco.30.6.609
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Incretin-based therapies encompass two new classes of antidiabetic drugs: glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, exenatide, and exenatide long-acting release), which are structurally related to GLP-1, and the dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin and saxagliptin), which limit the breakdown of endogenous GLP-1. To evaluate the safety and effectiveness of incretin-based therapies for the treatment of type 2 diabetes mellitus and the role of these therapies in clinical practice, a MEDLINE search (January 1985 November 2009) was conducted. Relevant references from the publications identified were also reviewed. Of 28 studies identified, 22 were randomized controlled trials. Data show that these therapies affect insulin secretion in a glucose-dependent manner, achieving clinically meaningful reductions in hemoglobin A(1c) levels, with very low rates of hypoglycemia. In addition, reductions in body weight have been observed with GLP-1 receptor agonists, which also exert a pronounced effect on systolic blood pressure. Various human and animal studies show that GLP-1 improves beta-cell function and increases beta-cell proliferation in vitro, which may slow disease progression. Thus, incretin-based therapies represent a promising addition to the available treatments for type 2 diabetes.
引用
收藏
页码:609 / 624
页数:16
相关论文
共 110 条
[1]   GLP-1: physiological effects and potential therapeutic applications [J].
Aaboe, Kasper ;
Krarup, Thure ;
Madsbad, Sten ;
Holst, Jens Juul .
DIABETES OBESITY & METABOLISM, 2008, 10 (11) :994-1003
[2]   The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].
Agerso, H ;
Jensen, LB ;
Elbrond, B ;
Rolan, P ;
Zdravkovic, M .
DIABETOLOGIA, 2002, 45 (02) :195-202
[3]  
*AM DIAB ASS, 2001, DIABETES CARE S1, V32, pS13
[4]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[5]  
[Anonymous], 1995, Diabetes, V44, P1249
[6]  
[Anonymous], 2009, BYETT EX PACK INS
[7]  
[Anonymous], 2009, ONGL SAX PACK INS
[8]   Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].
Aschner, Pablo ;
Kipnes, Mark S. ;
Lunceford, Jared K. ;
Sanchez, Matilde ;
Mickel, Carolyn ;
Williams-Herman, Debora E. .
DIABETES CARE, 2006, 29 (12) :2632-2637
[9]   Biology of incretins: GLP-1 and GIP [J].
Baggio, Laurie L. ;
Drucker, Daniel J. .
GASTROENTEROLOGY, 2007, 132 (06) :2131-2157
[10]   Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial [J].
Barnett, Anthony H. ;
Burger, Jude ;
Johns, Don ;
Brodows, Robert ;
Kendall, David M. ;
Roberts, Anthony ;
Trautmann, Michael E. .
CLINICAL THERAPEUTICS, 2007, 29 (11) :2333-2348